Analysts Set AstraZeneca PLC (LON:AZN) PT at £104.12

AstraZeneca PLC (LON:AZN) has earned a consensus rating of “Moderate Buy” from the nine ratings firms that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating on the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is GBX 7,935.67 ($97.65).

A number of brokerages have weighed in on AZN. Berenberg Bank restated a “buy” rating and issued a GBX 140 ($1.72) target price on shares of AstraZeneca in a research note on Monday. Shore Capital restated a “buy” rating on shares of AstraZeneca in a research report on Thursday, November 7th. Finally, JPMorgan Chase & Co. reiterated an “overweight” rating and set a £140 ($172.27) target price on shares of AstraZeneca in a research report on Friday, November 22nd.

Insider Buying and Selling at AstraZeneca

In related news, insider Pascal Soriot purchased 20,000 shares of AstraZeneca stock in a transaction that occurred on Thursday, November 14th. The shares were acquired at an average cost of £102.03 ($125.54) per share, for a total transaction of £2,040,600 ($2,510,889.63). Also, insider Tony Mok purchased 1,500 shares of the firm’s stock in a transaction on Tuesday, November 19th. The stock was bought at an average cost of £126.80 ($156.02) per share, for a total transaction of £190,200 ($234,034.70). Company insiders own 0.04% of the company’s stock.

AstraZeneca Trading Up 0.0 %

AstraZeneca stock opened at £109.88 ($135.20) on Friday. The stock has a market cap of £170.31 billion, a P/E ratio of 3,488.25, a PEG ratio of 0.86 and a beta of 0.17. AstraZeneca has a fifty-two week low of GBX 9,461 ($116.41) and a fifty-two week high of £133.88 ($164.73). The firm’s fifty day moving average price is £104.83 and its 200-day moving average price is £116.65. The company has a debt-to-equity ratio of 84.97, a quick ratio of 0.59 and a current ratio of 0.89.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.